Related Experiment Videos
Diabetes mellitus induced by low-dose interleukin-2
N Soni1, N J Meropol, M Porter
1Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Cancer Immunology, Immunotherapy : CII
|September 1, 1996
Summary
Interleukin-2 (IL-2) therapy, while generally safe, can trigger new-onset insulin-dependent diabetes in some patients. This study highlights a case where IL-2 induced diabetes linked to immune cell expansion and autoantibodies.
Area of Science:
- Immunology
- Endocrinology
- Oncology
Background:
- Interleukin-2 (IL-2) is a cytokine used for immunotherapy.
- Autoimmune disorders are potential side effects of immunomodulators.
- Diabetes mellitus has not been previously linked to single-agent IL-2 therapy.
Observation:
- A patient with advanced colorectal cancer received low-dose, daily subcutaneous IL-2.
- The patient developed insulin-requiring diabetes during IL-2 treatment.
- Hyperglycemia resolved upon IL-2 cessation and recurred upon reintroduction.
Findings:
- Diabetes onset correlated with T cell and natural killer cell expansion.
- Islet cell autoantibodies were detected in the patient.
- IL-2 may reverse anergy in autoreactive T cells, leading to autoimmunity.
Implications:
- Prolonged, daily low-dose IL-2 administration may induce autoimmune phenomena.
- This finding expands the known side effect profile of IL-2 therapy.
- Further research is needed to understand IL-2's role in iatrogenic autoimmunity.